MRK
Merck & Co., Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 30 ▲ 3 funds open new positions (13F)
- Aug 5 to Aug 13 ▼ 6 days of insider sells: $30.0M by 5 insiders, avg $131.34
- Aug 7 to Aug 19 ▲ 2 buys: Ro Khanna, Maria Elvira Salazar bought $15,001 - $50,000, last disclosed Sep 10
- Aug 20 2 analyst actions
- Aug 28 to Sep 4 ▼ 2 sells: Michael McCaul, Ro Khanna sold, last disclosed Oct 16
- Sep 22 to Sep 29 3 court rulings: HUMANA INC. v. MERCK & COMPANY, INC. et al; Kaiser Foundation Health Plan Inc v. Merck & Company Inc… and 1 more
- Sep 24 ▼ Maria Elvira Salazar sold $1,001 - $15,000, last disclosed Oct 8
- Oct 2 to Oct 7 ▲ 2 buys: Ro Khanna bought, last disclosed Nov 9
- Oct 15 ▲ The PTAB issued a Final Written Decision in PGR2025-00030, holding a…
- Oct 21 Trial readout: Results Pending: A Clinical Study of Efinopegdutide in Peo…
- Oct 24 Trial readout: Results Pending: Ensifentrine 3 mg (Phase 2), Completed 68…
- Nov 5 Trial readout: Results Pending: Sacituzumab tirumotecan (Phase 2), comple…
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $30.0M.
- InstitutionsMIXED
Q2 2026: 47 added (3 new), 35 trimmed or exited. Largest new: Qube Research & Technologies $134.2M, Temasek Holdings (Private) $104.9M.
- AnalystsBULLISH
25 of 35 rate it Buy or better. Median target $165.00 (+13%).
- Short sellersSTEADY
Short interest −0.8% to 26.60M shares. 2.4 days to cover, ≈1.1% of shares.
- TrendRANGE
0% below its 50-day average.
- SocialQUIET
Crowd 57° (neutral) this week from 3 mentions: 1 bullish, 0 bearish. No setup is alerting. Excludes 1 subscriber-only day.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Fisher Asset Management, LLC | ADD | $4.9B |
| Capital International Investors | DOUBLED | $2.0B |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | $833.3M |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | TRIM | $693.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $509.7M |
| CITIGROUP INC | ADD | $464.5M |
| NORDEA INVESTMENT MANAGEMENT AB | TRIM | $445.1M |
| Ensign Peak Advisors, Inc | ADD | $432.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
35 analystsPrice is inside the target range. Median implies +13%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Freedom Broker MAINTAIN | Hold |
| Nov 2, 2026 | Cantor Fitzgerald MAINTAIN | Neutral |
| Oct 30, 2026 | JP Morgan MAINTAIN | Overweight |
| Oct 30, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 30, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 26, 2026 | Barclays MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
DIAZ PAUL J Director Nov 1, 2026 | AWARD | $91.7K |
Coe Mary Ellen Director Sep 30, 2026 | AWARD | $30.0K |
Karsanbhai Surendralal Lanca Director Sep 30, 2026 | AWARD | $16.3K |
Seidman Christine E Director Sep 30, 2026 | AWARD | $8.1K |
Guindo Chirfi EVP, Access, Policy & Comms Aug 13, 2026 | SELL | $1.4M |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth Aug 12, 2026 | SELL | $79.2K |
DeLuca Richard R. EVP&Pres, Merck Animal Heallth Aug 12, 2026 | SELL | $1.5M |
Zachary Jennifer EVP, General Counsel Aug 12, 2026 | EXERCISE | $1.1M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
34 filings · 6 bullish · 2 bearish · 1 mixed · 25 neutral- NEUTRAL 144Nov 12, 2026
Richard R. DeLuca Jr., an officer of Merck, filed a Form 144 notice of intent to sell 58,185…
The filing is a routine advance notice of an insider sale; the actual sale may or may not occur. No material impact expected. Monitor for any subsequent Form 4 filings to confirm execution.
- NEUTRAL PTAB-TRIALNov 9, 2026
In a final written decision, the PTAB held all challenged claims (1, 2, 5, and 7–33) of Halozyme's…
The invalidation removes one patent from the ongoing Halozyme-Merck litigation, but many related patents remain in dispute. Monitor the remaining PGRs and the district court case for further…
- NEUTRAL 3Nov 3, 2026
Paul J. Diaz filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 200…
Routine initial ownership filing for a new insider. No trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Diaz.
- BEARISH INST-CLUSTERNov 3, 2026
A mixed institutional cluster for Merck in Q3 2026 shows three small-to-mid-sized asset managers…
The cluster shows active managers reducing Merck exposure after Q3 earnings that missed EPS consensus, despite a sales beat. The largest seller (Assenagon, -$119.2M) and the absence of insider…
All MRK filing & press-release reports (34)
- 144 reportNov 12, 2026
- PTAB-TRIAL reportNov 9, 2026
- 3 reportNov 3, 2026
- INST-CLUSTER reportNov 3, 2026
- 144 reportNov 2, 2026
- 8-K reportOct 29, 2026
- 3/A reportOct 22, 2026
- PTAB-TRIAL reportOct 21, 2026
- PTAB-TRIAL reportOct 15, 2026
- PTAB-TRIAL reportOct 15, 2026
- 8-K reportOct 13, 2026
- COURT-RULING reportSep 29, 2026
- COURT-RULING reportSep 28, 2026
- COURT-RULING reportSep 22, 2026
- COURT-RULING reportSep 11, 2026
- COURT-RULING reportSep 9, 2026
- COURT-RULING reportAug 27, 2026
- COURT-RULING reportAug 24, 2026
- Morgan Stanley upgrades MRK to Overweight, PT $179 (+17.6%)Aug 20, 2026
- COURT-RULING reportAug 13, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 12, 2026
- Daiwa Capital Upgrades MRK to Outperform, PT $143 (+9.6%)Aug 12, 2026
- CLUSTER reportAug 10, 2026
- CLUSTER reportAug 7, 2026
- COURT-RULING reportAug 6, 2026
- 8-K reportAug 4, 2026
- COURT-RULING reportMar 2, 2026
- COURT-RULING reportFeb 12, 2026
- COURT-RULING reportApr 8, 2026
- CICC initiates coverage on MRK at OutperformJun 24, 2026
- 8-K reportMay 22, 2026
- DEFA14A reportApr 8, 2026